BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37096846)

  • 21. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
    Zhang M; Wang N; Song P; Fu Y; Ren Y; Li Z; Wang J
    Cell Prolif; 2020 Sep; 53(9):e12855. PubMed ID: 32687248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EPHA2 antisense RNA modulates EPHA2 mRNA levels in basal-like/triple-negative breast cancer cells.
    Okuyama T; Sakamoto R; Kumagai K; Nishizawa M; Kimura T; Sugie T; Kimura T
    Biochimie; 2020 Dec; 179():169-180. PubMed ID: 33022313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MYBL2-induced PITPNA-AS1 upregulates SIK2 to exert oncogenic function in triple-negative breast cancer through miR-520d-5p and DDX54.
    Liu B; Yao P; Xiao F; Guo J; Wu L; Yang Y
    J Transl Med; 2021 Aug; 19(1):333. PubMed ID: 34353336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNA PRRT3-AS1 silencing inhibits prostate cancer cell proliferation and promotes apoptosis and autophagy.
    Fan L; Li H; Wang W
    Exp Physiol; 2020 May; 105(5):793-808. PubMed ID: 32086850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer.
    Xu S; Wang P; Zhang J; Wu H; Sui S; Zhang J; Wang Q; Qiao K; Yang W; Xu H; Pang D
    Mol Cancer; 2019 Apr; 18(1):89. PubMed ID: 30999914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SP1-Induced Upregulation of LncRNA AFAP1-AS1 Promotes Tumor Progression in Triple-Negative Breast Cancer by Regulating mTOR Pathway.
    Li F; Xian D; Huang J; Nie L; Xie T; Sun Q; Zhang X; Zhou Y
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling.
    Vishnubalaji R; Alajez NM
    Sci Rep; 2021 Jul; 11(1):15410. PubMed ID: 34326372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
    Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
    Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
    Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
    Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ursolic Acid Enhances Cytotoxicity of Doxorubicin-Resistant Triple-Negative Breast Cancer Cells via
    Lu Q; Chen W; Ji Y; Liu Y; Xue X
    Cancer Biother Radiopharm; 2022 Oct; 37(8):673-683. PubMed ID: 33493421
    [No Abstract]   [Full Text] [Related]  

  • 31. lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p.
    Peng Y; Huang X; Wang H
    BMC Mol Cell Biol; 2022 Jul; 23(1):34. PubMed ID: 35896973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis.
    Hu J; Huang H; Xi Z; Ma S; Ming J; Dong F; Guo H; Zhang H; Zhao E; Yao G; Yang L; Zhang F; Zheng W; Chen H; Huang T; Li L
    Cell Death Dis; 2022 Sep; 13(9):800. PubMed ID: 36123344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LncRNA MCM3AP-AS1 Downregulates LncRNA MEG3 in Triple Negative Breast Cancer to Inhibit the Proliferation of Cancer Cells.
    Ren G; Han G; Song Z; Zang A; Liu B; Hu L; Jia L; Hong D; Yang L; Qie S
    Crit Rev Eukaryot Gene Expr; 2021; 31(4):81-87. PubMed ID: 34587438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy.
    Liu X; Zhang G; Yu T; Liu J; Chai X; Yin D; Zhang C
    Int J Biol Macromol; 2023 Oct; 250():126147. PubMed ID: 37544559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.
    Chen J; Zhu M; Zou L; Xia J; Huang J; Deng Q; Xu R
    Acta Biochim Biophys Sin (Shanghai); 2020 Aug; 52(8):801-809. PubMed ID: 32632453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA SEMA3B-AS1 suppresses the tumor-initiating characteristics of triple negative breast cancer via engaging in MLL4-mediated H3K4 trimethylation.
    Chen D; Chen Z; Wang Z; Hong C; Wang Q; Yang P; Huang Z; Lian W; Huang Y; Fu W; Li J; Hong Z
    Mol Carcinog; 2024 Mar; 63(3):371-383. PubMed ID: 37975495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
    Wu D; Jia H; Zhang Z; Li S
    Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication.
    Sheng X; Dai H; Du Y; Peng J; Sha R; Yang F; Zhou L; Lin Y; Xu S; Wu Y; Yin W; Lu J
    J Exp Clin Cancer Res; 2021 Jun; 40(1):205. PubMed ID: 34162418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-526b targets lncRNA SLC16A1-AS1 to suppress cell proliferation in triple-negative breast cancer.
    Zhao X; Fu L; Zhai L; Yang X; Gao R
    J Biochem Mol Toxicol; 2023 Mar; 37(3):e23247. PubMed ID: 36654514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
    Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
    Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.